John D Imig

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7021901/publications.pdf

Version: 2024-02-01

261 papers	11,400 citations	20759 60 h-index	40881 93 g-index
323 all docs	323 docs citations	323 times ranked	7709 citing authors

#	Article	IF	Citations
1	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Current Opinion in Nephrology and Hypertension, 2022, 31, 36-46.	1.0	11
2	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion on Therapeutic Targets, 2022, 26, 13-28.	1.5	5
3	Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochemical Pharmacology, 2022, 195, 114866.	2.0	13
4	Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury. Advances in Pharmacology, 2022, , .	1.2	0
5	Editorial: Interactions Between Podocytes, Mesangial Cells, and Glomerular Endothelial Cells in Glomerular Diseases. Frontiers in Physiology, 2022, 13, 849693.	1.3	3
6	SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection. Clinical Science, 2022, 136, 431-434.	1.8	6
7	Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats. Frontiers in Physiology, 2021, 12, 622882.	1.3	7
8	Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores. Hypertension, 2021, 77, 582-593.	1.3	9
9	Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. International Journal of Molecular Sciences, 2021, 22, 2793.	1.8	13
10	Diabetes risk associated with plasma epoxylipid levels. EBioMedicine, 2021, 66, 103331.	2.7	1
11	Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation. Biomedicines, 2021, 9, 1053.	1.4	11
12	Multi-Target Drugs for Kidney Diseases. Kidney360, 2021, 2, 1645-1653.	0.9	8
13	Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats. British Journal of Pharmacology, 2021, 178, 4468-4484.	2.7	6
14	Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes. Cells, 2021, 10, 2659.	1.8	8
15	Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. Frontiers in Immunology, 2021, 12, 747794.	2.2	3
16	Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats. Frontiers in Pharmacology, 2021, 12, 798642.	1.6	4
17	Abstract 10030: A Novel Multi-Target Drug Prevents Cancer Therapy-Induced Hypertension and Renal Damage. Circulation, 2021, 144, .	1.6	0
18	Dual sEH/COX-2 Inhibition Using PTUPBâ€"A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. Frontiers in Pharmacology, 2021, 12, 744776.	1.6	4

#	Article	IF	Citations
19	Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors. Frontiers in Pharmacology, 2020, 11, 598858.	1.6	8
20	Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers, 2020, 12, 3412.	1.7	3
21	Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. Journal of Hypertension, 2020, 38, 1802-1810.	0.3	12
22	Editorial: Renal Function in Acute and Chronic Kidney Diseases. Frontiers in Physiology, 2020, 11, 625353.	1.3	0
23	Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics. Hypertension, 2020, 76, 3-15.	1.3	16
24	Dual soluble epoxide hydrolase inhibitor/PPAR-Î³ agonist attenuates renal fibrosis. Prostaglandins and Other Lipid Mediators, 2020, 150, 106472.	1.0	18
25	Multi-Target Approaches in Metabolic Syndrome. Frontiers in Pharmacology, 2020, 11, 554961.	1.6	59
26	Eicosanoid blood vessel regulation in physiological and pathological states. Clinical Science, 2020, 134, 2707-2727.	1.8	36
27	A sorafenib-induced model of glomerular kidney disease. Bulletin of Taras Shevchenko National University of Kyiv Series Biology, 2020, 81, 25-31.	0.1	1
28	COMBINED FARNESOID X RECEPTOR AGONIST AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR TREATS PROGRESSIVE RENAL FIBROSIS. FASEB Journal, 2020, 34, 1-1.	0.2	0
29	The effect of compound DM509 on kidney fibrosis in the conditions of the experimental model. Bulletin of Taras Shevchenko National University of Kyiv Series Biology, 2020, 80, 10-15.	0.1	4
30	REVERSAL OF UNILATERAL URETERAL OBSTRUCTION LEADS TO SALTâ€SENSITIVE HYPERTENSION. FASEB Journal, 2020, 34, 1-1.	0.2	0
31	DUAL ACTING COXâ€2 AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR ATTENUATES GLOMERULAR INJURY IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS. FASEB Journal, 2020, 34, 1-1.	0.2	0
32	Effective Antihypertensive Treatment with Epoxyeicosatrienoic Acid Analog (EETâ€A) and 20â€HETE Antagonist (AAA) of Spontaneously Hypertensive Rats (SHR). FASEB Journal, 2020, 34, 1-1.	0.2	0
33	A DUAL COXâ€2/sEH INHIBITOR TREATED KIDNEY INJURY IN A DRUGâ€INDUCED GLOMERULAR DISEASE MODEL. FASEB Journal, 2020, 34, 1-1.	0.2	0
34	Fructose Consumption Increases Blood Pressure and Induces Changes in Renal Microvascular Function. FASEB Journal, 2020, 34, 1-1.	0.2	0
35	Abstract P056: Voltage-gated Chloride Channel 6 Regulates Intracellular Calcium Signaling In Vascular Smooth Muscle Cells And Prevents Arterial Stiffening. Hypertension, 2020, 76, .	1.3	0
36	Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart. Scientific Reports, 2019, 9, 11004.	1.6	18

#	Article	IF	Citations
37	Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. Kidney and Blood Pressure Research, 2019, 44, 792-809.	0.9	14
38	Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. Frontiers in Pharmacology, 2019, 10, 18.	1.6	9
39	A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochemical Pharmacology, 2019, 166, 212-221.	2.0	20
40	Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. Frontiers in Pharmacology, 2019, 10, 512.	1.6	17
41	Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats. Frontiers in Pharmacology, 2019, 10, 159.	1.6	13
42	Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clinical Science, 2019, 133, 939-951.	1.8	19
43	Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney and Blood Pressure Research, 2019, 44, 1493-1505.	0.9	3
44	Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiologica, 2019, 225, e13203.	1.8	5
45	A Dual Soluble Epoxide Hydrolase Inhibitor/PPARâ€Î³ Agonist Prevents Renal Fibrosis in Mouse Unilateral Ureteral Obstruction Model. FASEB Journal, 2019, 33, 678.12.	0.2	1
46	Epoxyeicosanoids in Hypertension. Physiological Research, 2019, 68, 695-704.	0.4	34
47	Glomerular Mesangial Proliferation is Mitigated by sEH/COXâ€2 Dualâ€Inhibition. FASEB Journal, 2019, 33, 671.7.	0.2	0
48	A Dual Farnesoid X Receptor Agonist /Soluble Epoxide Hydrolase Inhibitor Prevents Nonâ€Alcoholic Steatohepatitis in Mice. FASEB Journal, 2019, 33, 506.3.	0.2	0
49	EET Analogs and the Dualâ€Inhibition of sEH/COXâ€2 for the Treatment of Focal Segmental Glomerular Sclerosis. FASEB Journal, 2019, 33, 863.8.	0.2	0
50	A Novel Dual Soluble Epoxide Hydrolase Inhibitor/Cyclooxygenaseâ€2 Inhibitor Treats Type 2 Diabetic Complications in Obese ZSF1 Rats. FASEB Journal, 2019, 33, 514.2.	0.2	0
51	Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. Nephrology Dialysis Transplantation, 2018, 33, 1333-1343.	0.4	8
52	Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney and Blood Pressure Research, 2018, 43, 329-349.	0.9	10
53	Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. Journal of Hypertension, 2018, 36, 1326-1341.	0.3	26
54	SP074SOLUBLE EPOXIDE HYDROLASE INHIBITION AUGMENTS RAS BLOCKADE RENOPROTECTION INSUBTOTALLY NEPHRECTOMIZED REN-2 TRANSGENIC HYPERTENSIVE RATS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2018, 33, i370-i370.	0.4	0

#	Article	IF	Citations
55	20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Bioscience Reports, 2018, 38, .	1.1	13
56	Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. , 2018, 192, 1-19.		67
57	Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1Î± via downregulation of prolyl hydroxylase 3. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H1148-H1158.	1.5	21
58	A novel dual PPAR-Î³ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia, 2018, 61, 2235-2246.	2.9	40
59	Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats. Diabetes, 2018, 67, 2206-2212.	0.3	11
60	Molecular Pathways in Hypertensive Renal Damage. Updates in Hypertension and Cardiovascular Protection, 2018, , 445-463.	0.1	3
61	The Effect of Voltageâ€Sensitive Chloride Channel 6 on Development of Saltâ€Sensitive Hypertension. FASEB Journal, 2018, 32, 750.23.	0.2	0
62	Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. Diabetologia, 2017, 60, 1066-1075.	2.9	35
63	Orally Active Epoxyeicosatrienoic Acid Analogs. Journal of Cardiovascular Pharmacology, 2017, 70, 211-224.	0.8	42
64	Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2758-2765.	1.1	21
65	Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition. Frontiers in Pharmacology, 2017, 8, 406.	1.6	36
66	Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. International Journal of Molecular Sciences, 2016, 17, 751.	1.8	27
67	Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response?. American Journal of Physiology - Renal Physiology, 2016, 310, F1013-F1015.	1.3	1
68	The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. American Journal of Physiology - Renal Physiology, 2016, 311, F576-F585.	1.3	17
69	Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Ratsâ€™ Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. American Journal of the Medical Sciences, 2016, 351, 513-519.	0.4	8
70	Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clinical Science, 2016, 130, 587-599.	1.8	28
71	Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. Advances in Pharmacology, 2016, 77, 105-141.	1.2	62
72	Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1695-H1701.	1.5	4

#	Article	IF	Citations
73	A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins and Other Lipid Mediators, 2016, 125, 40-47.	1.0	37
74	Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established. Journal of Hypertension, 2016, 34, 2008-2025.	0.3	22
75	Mitigation of normal tissue radiation injury: evidence from rat radiation nephropathy models. Journal of Radiation Oncology, 2016, 5, 1-8.	0.7	1
76	p66Shc regulates renal vascular tone in hypertension-induced nephropathy. Journal of Clinical Investigation, 2016, 126, 2533-2546.	3.9	36
77	Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. , 2015, 6, 423-441.		21
78	Reply to â€œLetter to the editor: â€˜Concern regarding quantification of urinary nephrin by commercially available ELISAâ€™â€• American Journal of Physiology - Renal Physiology, 2015, 309, F271-F271.	1.3	0
79	Hypertension Is a Major Contributor to 20-Hydroxyeicosatetraenoic Acidâ€“Mediated Kidney Injury in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 597-610.	3.0	44
80	Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. American Journal of Physiology - Renal Physiology, 2015, 308, F131-F139.	1.3	64
81	Epoxyeicosatrienoic Acids, Hypertension, and Kidney Injury. Hypertension, 2015, 65, 476-482.	1.3	71
82	Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. Purinergic Signalling, 2015, 11, 519-531.	1.1	9
83	Tumour necrosis factorâ€‹Î± contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia. Acta Physiologica, 2015, 214, 97-108.	1.8	19
84	Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascular Pharmacology, 2015, 73, 45-56.	1.0	14
85	Elevated Aminopeptidase P Attenuates Cerebral Arterial Responses to Bradykinin in Fawn-Hooded Hypertensive Rats. PLoS ONE, 2015, 10, e0145335.	1.1	1
86	Radiation Nephropathy is Mitigated by Epoxyeicosatrienoic acid Analog. FASEB Journal, 2015, 29, 938.4.	0.2	0
87	The Cyp2c44 Epoxygenase Regulates Epithelial Sodium Channel Activity and the Blood Pressure Responses to Increased Dietary Salt. Journal of Biological Chemistry, 2014, 289, 4377-4386.	1.6	51
88	Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Frontiers in Pharmacology, 2014, 5, 216.	1.6	34
89	Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Renâ€2 transgenic hypertensive rats. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 227-237.	0.9	37
90	Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. American Journal of Physiology - Renal Physiology, 2014, 307, F971-F980.	1.3	81

#	Article	IF	Citations
91	Fructose Stimulates Na/H Exchange Activity and Sensitizes the Proximal Tubule to Angiotensin II. Hypertension, 2014, 63, e68-73.	1.3	68
92	Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clinical Science, 2014, 127, 463-474.	1.8	63
93	Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: Studies in Cyp1a1-Ren-2 transgenic rats. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 1003-1013.	0.9	20
94	Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia, 2014, 57, 413-423.	2.9	125
95	Azilsartan Improves Glycemic Status and Reduces Kidney Damage in Zucker Diabetic Fatty Rats. American Journal of Hypertension, 2014, 27, 1087-1095.	1.0	19
96	14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) Surrogates: Carboxylate Modifications. Journal of Medicinal Chemistry, 2014, 57, 6965-6972.	2.9	30
97	Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat. Cardiovascular Drugs and Therapy, 2014, 28, 313-322.	1.3	23
98	A dual COXâ€sEH inhibitor improved glycemic status and reduced kidney injury in Zucker diabetic fatty rat (689.4). FASEB Journal, 2014, 28, 689.4.	0.2	0
99	Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB Journal, 2013, 27, 2946-2956.	0.2	70
100	Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 2-7.	1.0	58
101	Immune and Inflammatory Role in Renal Disease. , 2013, 3, 957-976.		254
102	Anti-inflammatory Effects of Ï‰-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-IIâ€“Dependent Hypertension. Journal of Cardiovascular Pharmacology, 2013, 62, 285-297.	0.8	92
103	Orally Active Epoxyeicosatrienoic Acid Analog Attenuates Kidney Injury in Hypertensive Dahl Saltâ€“Sensitive Rat. Hypertension, 2013, 62, 905-913.	1.3	56
104	Antihypertensive action of soluble epoxide hydrolase inhibition in <scp>R</scp>enâ€2 transgenic rats is mediated by suppression of the intrarenal reninâ€“angiotensin system. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 273-281.	0.9	19
105	Afferent arteriolar responses to Î²,Î³-methylene ATP and 20-HETE are not blocked by ENaC inhibition. Physiological Reports, 2013, 1, e00082.	0.7	9
106	Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. Journal of Hypertension, 2013, 31, 321-332.	0.3	19
107	A novel epoxyeicosatrienoic acid analog attenuates hypertension and renal injury in Cyp2c44 KO mice. FASEB Journal, 2013, 27, 880.1.	0.2	0
108	11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1574-H1583.	1.5	17

#	Article	IF	Citations
109	Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor Î³ agonist improve vascular function and decrease renal injury in hypertensive obese rats. Experimental Biology and Medicine, 2012, 237, 1402-1412.	1.1	54
110	Soluble Epoxide Hydrolase Inhibition Exhibits Antihypertensive Actions Independently of Nitric Oxide in Mice with Renovascular Hypertension. Kidney and Blood Pressure Research, 2012, 35, 595-607.	0.9	25
111	Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clinical Science, 2012, 122, 513-527.	1.8	63
112	Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology. Physiological Reviews, 2012, 92, 101-130.	13.1	302
113	Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 454-461.	0.9	20
114	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.. FASEB Journal, 2012, 26, 686.4.	0.2	0
115	Novel Orally Active Epoxyeicosatrienoic Acid (EET) Analogs Attenuate Cisplatin Nephrotoxicity. FASEB Journal, 2012, 26, 851.7.	0.2	0
116	Inhibition of soluble epoxide hydrolase improves the impaired pressureâ€“natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. Journal of Hypertension, 2011, 29, 1590-1601.	0.3	37
117	Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Renâ€2 transgenic rats with inducible hypertension. Journal of Physiology, 2011, 589, 207-219.	1.3	35
118	Telmisartan Provides Better Renal Protection Than Valsartan in a Rat Model of Metabolic Syndrome. American Journal of Hypertension, 2011, 24, 816-821.	1.0	25
119	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R1307-R1317.	0.9	65
120	Cytochrome P450 eicosanoids and cerebral vascular function. Expert Reviews in Molecular Medicine, 2011, 13, e7.	1.6	64
121	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9038-9043.	3.3	130
122	Glomerular Expression of Kidney Injury Molecule-1 and Podocytopenia in Diabetic Glomerulopathy. American Journal of Nephrology, 2011, 34, 268-280.	1.4	49
123	Role of cytochromeP-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R1468-R1475.	0.9	34
124	Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. American Journal of Physiology - Renal Physiology, 2011, 301, F765-F772.	1.3	4
125	CYP Pathway Modulators Alter Development and Angiogenesis in Zebrafish Embryos. FASEB Journal, 2011, 25, lb437.	0.2	0
126	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocinâ€induced type 1 diabetes. FASEB Journal, 2011, 25, 664.10.	0.2	0

#	Article	IF	Citations
127	Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. Journal of Hypertension, 2010, 28, 582-593.	0.3	21
128	Targeting Epoxides for Organ Damage in Hypertension. Journal of Cardiovascular Pharmacology, 2010, 56, 329-335.	0.8	53
129	Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clinical Science, 2010, 118, 291-301.	1.8	76
130	Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertensioninduced end-organ damage in Ren-2 transgenic rats. Clinical Science, 2010, 118, 617-632.	1.8	43
131	Development of Epoxyeicosatrienoic Acid Analogs with in Vivo Anti-Hypertensive Actions. Frontiers in Physiology, 2010, 1, 157.	1.3	47
132	20-Hydroxyeicosatetraenoic Acid and Angiotensin. Hypertension, 2010, 56, 822-823.	1.3	2
133	Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertensionâ€induced renal injury in mice. FASEB Journal, 2010, 24, 3770-3781.	0.2	126
134	Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. American Journal of Physiology - Renal Physiology, 2010, 298, F86-F94.	1.3	44
135	Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. PPAR Research, 2010, 2010, 1-9.	1.1	14
136	Epoxyeicosatrienoic Acid Analogs and Vascular Function. Current Medicinal Chemistry, 2010, 17, 1181-1190.	1.2	103
137	Impaired mesenteric resistance artery relaxation to KATP channel activation in cardiometabolic syndrome is improved by rosiglitazone treatment. FASEB Journal, 2010, 24, 978.9.	0.2	0
138	Soluble Epoxide Hydrolase Inhibition (SEHi) and Thiazolidinedione (TZD) in combination provide greater renal injury protection in Spontaneously Hypertensive Obese (SHROB) Rats.. FASEB Journal, 2010, 24, 812.9.	0.2	0
139	Attenuated endothelinâ€1 (ETâ€1) vasoconstrictor responses in cardiometabolic syndrome are attributed to increased ETâ€B receptors. FASEB Journal, 2010, 24, 978.10.	0.2	0
140	Vascular Endothelial Growth Factor (VEGF) Inhibitors Induce Hypertension, Afferent Arteriolar Dysfunction, and Glomerular Injury. FASEB Journal, 2010, 24, 575.9.	0.2	0
141	The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension. Pharmaceuticals, 2009, 2, 217-227.	1.7	18
142	Increased Renal Proximal Convoluted Tubule Transport Contributes to Hypertension in Cyp4a14 Knockout Mice. Nephron Physiology, 2009, 113, p23-p28.	1.5	21
143	Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. American Journal of Physiology - Renal Physiology, 2009, 297, F740-F748.	1.3	121
144	Adenosine 2A Receptors and Epoxyeicosatrienoic Acids. Hypertension, 2009, 54, 1223-1225.	1.3	2

#	Article	IF	Citations
145	Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. European Journal of Pharmacology, 2009, 607, 143-150.	1.7	37
146	Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nature Reviews Drug Discovery, 2009, 8, 794-805.	21.5	527
147	OBESITY INDUCED RENAL OXIDATIVE STRESS CONTRIBUTES TO RENAL INJURY IN SALTâ€SENSITIVE HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 724-728.	0.9	24
148	Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural Protection. American Journal of Pathology, 2009, 174, 2086-2095.	1.9	102
149	Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Gotoâ€“Kakizaki rats. Clinical Science, 2009, 116, 61-70.	1.8	75
150	SPARC deficiency ameliorates renal damage resulting from angiotensin II and a high salt diet. FASEB Journal, 2009, 23, 604.1.	0.2	0
151	Renal mechanisms of antihypertensive effects caused by inhibition of soluble epoxide hydrolase in Cyp1a1â€Renâ€2 transgenic rats.. FASEB Journal, 2009, 23, 1016.4.	0.2	0
152	LCâ€MS measurement of the epoxyeicosatrienoic acid mimetic EETâ€8â€ZEâ€Ð in rat serum. FASEB Journal, 2009, 23, 1019.13.	0.2	0
153	Development of combined soluble epoxide hydrolase inhibitors and epoxide analogs with vasodilator activity. FASEB Journal, 2009, 23, 766.2.	0.2	0
154	Epoxyeicosatrienoic acids (EET) contribute to flowâ€induced dilation in mice mesenteric resistance artery. FASEB Journal, 2009, 23, 932.1.	0.2	0
155	Afferent Arteriolar Dilation to 11, 12-EET Analogs Involves PP2A Activity and Ca2 +-Activated K+Channels. Microcirculation, 2008, 15, 137-150.	1.0	61
156	SPARC Ameliorates Ovarian Cancer-Associated Inflammation. Neoplasia, 2008, 10, 1092-1104.	2.3	58
157	Identification of Novel Endogenous Cytochrome P450 Arachidonate Metabolites with High Affinity for Cannabinoid Receptors. Journal of Biological Chemistry, 2008, 283, 24514-24524.	1.6	65
158	The Renal Microcirculation. , 2008, , 550-683.		27
159	Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB Journal, 2008, 22, 4096-4108.	0.2	53
160	TNF-Î± inhibition reduces renal injury in DOCA-salt hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R76-R83.	0.9	121
161	Endothelial Dysfunction and the Development of Renal Injury in Spontaneously Hypertensive Rats Fed a High-Fat Diet. Hypertension, 2008, 51, 352-359.	1.3	99
162	Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 165-174.	1.5	52

#	Article	IF	Citations
163	Soluble Epoxide Inhibition Differentially Modulates Flow Induced Vascular Remodeling in Spontaneously Hypertensive Stroke Prone Rats and Wistar Kyoto Rats. FASEB Journal, 2008, 22, 479.42.	0.2	0
164	Soluble epoxide hydrolase inhibition attenuates the development of renovascular hypertension in 2K1C rats.. FASEB Journal, 2008, 22, 479.7.	0.2	0
165	Simvastatin and Tempol Protect Against Endothelial Dysfunction and Renal Injury in a Model of Obesity and Hypertension. FASEB Journal, 2008, 22, 947.8.	0.2	0
166	Soluble Epoxide Hydrolase Inhibition Modulates Gene Expression of Antiâ€Apoptotic and Apoptotic Factors. FASEB Journal, 2008, 22, 733.11.	0.2	1
167	Soluble epoxide hydrolase inhibitor improves cardiac ischemic tolerance in Renâ€2 transgenic rats. FASEB Journal, 2008, 22, 479.6.	0.2	0
168	The divergent role of epoxyeicosatrienoic acids in the regulation of renal function in normotensive and twoâ€kidney oneâ€clip Goldblatt hypertensive rats. FASEB Journal, 2008, 22, 761.1.	0.2	0
169	Ether epoxyeicosatrienoic acid (EET) analogs lower blood pressure when administered inâ€vivo to the spontaneously hypertensive rats. FASEB Journal, 2008, 22, 479.44.	0.2	2
170	Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney International, 2007, 72, 683-689.	2.6	108
171	Chemokine Receptor 2b Inhibition Provides Renal Protection in Angiotensin IIâ€“Salt Hypertension. Hypertension, 2007, 50, 1069-1076.	1.3	70
172	Novel Nitric Oxide Synthaseâ€“Dependent Mechanism of Vasorelaxation in Small Arteries From Hypertensive Rats. Hypertension, 2007, 49, 893-901.	1.3	42
173	Normalization of the Ovarian Cancer Microenvironment by SPARC. Molecular Cancer Research, 2007, 5, 1015-1030.	1.5	83
174	IL6 Suppression Provides Renal Protection Independent of Blood Pressure in a Murine Model of Salt-Sensitive Hypertension. Kidney and Blood Pressure Research, 2007, 30, 195-202.	0.9	17
175	The Roles of Intrarenal 20-Hydroxyeicosatetraenoic and Epoxyeicosatrienoic Acids in the Regulation of Renal Function in Hypertensive Ren-2 Transgenic Rats. Kidney and Blood Pressure Research, 2007, 30, 335-346.	0.9	10
176	Secreted Protein Acidic and Rich in Cysteine Deficiency Ameliorates Renal Inflammation and Fibrosis in Angiotensin Hypertension. American Journal of Pathology, 2007, 171, 1104-1112.	1.9	56
177	Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. Vascular Pharmacology, 2007, 46, 144-151.	1.0	14
178	Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascular Pharmacology, 2007, 47, 145-159.	1.0	35
179	Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins and Other Lipid Mediators, 2007, 83, 50-61.	1.0	45
180	Obesity, Insulin Resistance, and Renal Function. Microcirculation, 2007, 14, 349-362.	1.0	72

#	Article	IF	Citations
181	Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. Journal of Clinical Investigation, 2007, 117, 2496-2505.	3.9	94
182	Dietary fat increases renal injury in SHR in the absence of changes in insulin sensitivity or blood pressure. FASEB Journal, 2007, 21, A1194.	0.2	0
183	Rosaglitazone (RGZ) decreases renal damage in spontaneously diabetic Gotoâ€Kakizaki (GK) rats. FASEB Journal, 2007, 21, A1194.	0.2	0
184	Peroxisome proliferatorsâ€activated receptorâ€alpha activation increases renal CYP2C23 and decreases cyclin D1 and blood pressure in Zucker diabetic fatty rats. FASEB Journal, 2007, 21, A842.	0.2	0
185	Longâ€term high fat diet treatment activates NF kappa B signaling and increases endothelial dysfunction in angiotensin II hypertensive rats. FASEB Journal, 2007, 21, A1196.	0.2	0
186	High fat diet induces insulin resistance and heightened renal inflammation in angiotensin II hypertensive rats. FASEB Journal, 2007, 21, A504.	0.2	0
187	Eicosanoids and renal vascular function in diseases. Clinical Science, 2006, 111, 21-34.	1.8	83
188	Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease. Current Enzyme Inhibition, 2006, 2, 73-77.	0.3	1
189	Cardiovascular Therapeutic Aspects of Soluble Epoxide Hydrolase Inhibitors. Cardiovascular Drug Reviews, 2006, 24, 169-188.	4.4	86
190	PPAR-Î± activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H2187-H2195.	1.5	49
191	Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H935-H940.	1.5	218
192	Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R435-R441.	0.9	32
193	Tumor Necrosis Factor Î± Blockade Increases Renal Cyp2c23 Expression and Slows the Progression of Renal Damage in Salt-Sensitive Hypertension. Hypertension, 2006, 47, 557-562.	1.3	110
194	Increased RhoA/Rho-Kinase Signaling Mediates Spontaneous Tone in Aorta from Angiotensin II-Induced Hypertensive Rats. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 288-295.	1.3	85
195	Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB Journal, 2006, 20, 539-541.	0.2	21
196	Substituted Adamantyl-Urea Inhibitors of the Soluble Epoxide Hydrolase Dilate Mesenteric Resistance Vessels. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1307-1314.	1.3	43
197	Ureaâ€based soluble epoxide hydrolase inhibitors dilate mesenteric resistance vessels. FASEB Journal, 2006, 20, A669.	0.2	1
198	Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. FASEB Journal, 2006, 20, .	0.2	3

#	Article	IF	Citations
199	An Epoxide Hydrolase Inhibitor, 12-(3-Adamantan-1-yl-ureido)dodecanoic Acid (AUDA), Reduces Ischemic Cerebral Infarct Size in Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2005, 46, 842-848.	0.8	117
200	ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. British Journal of Pharmacology, 2005, 146, 1019-1026.	2.7	89
201	Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 288, R188-R196.	0.9	71
202	An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension. Hypertension, 2005, 46, 975-981.	1.3	223
203	Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. American Journal of Physiology - Renal Physiology, 2005, 289, F760-F767.	1.3	25
204	L-type calcium channels in the renal microcirculatory response to endothelin. American Journal of Physiology - Renal Physiology, 2005, 288, F771-F777.	1.3	27
205	Impaired Ca 2+ Signaling Attenuates P2X Receptorâ€“Mediated Vasoconstriction of Afferent Arterioles in Angiotensin II Hypertension. Hypertension, 2005, 46, 562-568.	1.3	39
206	Peroxisome Proliferator-Activated Receptor-Î± Activation Reduces Salt-Dependent Hypertension During Chronic Endothelin B Receptor Blockade. Hypertension, 2005, 46, 366-371.	1.3	35
207	Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. American Journal of Physiology - Renal Physiology, 2005, 289, F496-F503.	1.3	208
208	CYP450, COX-2 and Obesity Related Renal Damage. Toxicology Mechanisms and Methods, 2005, 15, 125-136.	1.3	9
209	Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. Journal of Applied Physiology, 2004, 97, 1268-1274.	1.2	21
210	ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses. Hypertension, 2004, 43, 533-535.	1.3	43
211	P2X Receptor-Stimulated Calcium Responses in Preglomerular Vascular Smooth Muscle Cells Involves 20-Hydroxyeicosatetraenoic Acid. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 1211-1217.	1.3	31
212	20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R3-R5.	0.9	14
213	Renal autoregulation in P2X1 knockout mice. Acta Physiologica Scandinavica, 2004, 181, 445-453.	2.3	62
214	Altered Kidney CYP2C and Cyclooxygenaseâ€2 Levels Are Associated with Obesityâ€Related Albuminuria. Obesity, 2004, 12, 1278-1289.	4.0	45
215	Elevated arterial pressure impairs autoregulation independently of AT1 receptor activation. Journal of Hypertension, 2004, 22, 811-818.	0.3	30
216	Rofecoxib decreases renal injury in obese Zucker rats. Clinical Science, 2004, 107, 561-570.	1.8	45

#	Article	IF	Citations
217	Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. Journal of the American Society of Nephrology: JASN, 2004, 15, 1244-53.	3.0	153
218	The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. Peptides, 2003, 24, 1141-1147.	1.2	18
219	Salt-Sensitive Hypertension After Exposure to Angiotensin Is Associated With Inability to Upregulate Renal Epoxygenases. Hypertension, 2003, 42, 775-780.	1.3	34
220	Decreased Renal Cytochrome P450 2C Enzymes and Impaired Vasodilation Are Associated With Angiotensin Salt-Sensitive Hypertension. Hypertension, 2003, 41, 709-714.	1.3	102
221	12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. Journal of Lipid Research, 2003, 44, 2391-2399.	2.0	45
222	Downregulation of Renal CYP-Derived Eicosanoid Synthesis in Rats With Diet-Induced Hypertension. Hypertension, 2003, 42, 594-599.	1.3	66
223	Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. Journal of Clinical Investigation, 2003, 112, 1895-1905.	3.9	144
224	Ang II Accumulation in Rat Renal Endosomes During Ang II-Induced Hypertension. Hypertension, 2002, 39, 116-121.	1.3	160
225	Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension. Hypertension, 2002, 39, 690-694.	1.3	373
226	Contribution of prostaglandin EP₂receptors to renal microvascular reactivity in mice. American Journal of Physiology - Renal Physiology, 2002, 283, F415-F422.	1.3	50
227	RenalAT1Receptor Protein Expression During the Early Stage of Diabetes Mellitus. International Journal of Experimental Diabetes Research, 2002, 3, 97-108.	1.0	39
228	Adaptations of the renal microcirculation to hypertension. Microcirculation, 2002, 9, 315-28.	1.0	11
229	Adaptations of the Renal Microcirculation to Hypertension. Microcirculation, 2002, 9, 315-328.	1.0	18
230	The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H2089-H2096.	1.5	42
231	Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. American Journal of Physiology - Renal Physiology, 2001, 280, F1054-F1061.	1.3	40
232	Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. Journal of Hypertension, 2001, 19, 983-992.	0.3	55
233	Epoxygenase Metabolites Contribute to Nitric Oxide-Independent Afferent Arteriolar Vasodilation in Response to Bradykinin. Journal of Vascular Research, 2001, 38, 247-255.	0.6	110
234	Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5211-5216.	3.3	228

#	Article	IF	Citations
235	Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney International, 2000, 58, 2320-2330.	2.6	118
236	Postglomerular vasoconstriction to angiotensin II and norepinephrine depends on intracellular calcium release. General Pharmacology, 2000, 34, 409-415.	0.7	20
237	Epoxygenase Metabolites: Epithelial and Vascular Actions. Molecular Biotechnology, 2000, 16, 233-252.	1.3	41
238	Eicosanoid regulation of the renal vasculature. American Journal of Physiology - Renal Physiology, 2000, 279, F965-F981.	1.3	151
239	Cytochrome P450 and Cyclooxygenase Metabolites Contribute to the Endothelin-1 Afferent Arteriolar Vasoconstrictor and Calcium Responses. Hypertension, 2000, 35, 307-312.	1.3	81
240	Endothelin-Mediated Calcium Signaling in Preglomerular Smooth Muscle Cells. Hypertension, 2000, 35, 280-286.	1.3	42
241	Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. American Journal of Hypertension, 2000, 13, 810-818.	1.0	44
242	ATP-mediated Ca2+signaling in preglomerular smooth muscle cells. American Journal of Physiology - Renal Physiology, 1999, 276, F450-F456.	1.3	15
243	Renal endosomes contain angiotensin peptides, converting enzyme, and AT_{1A}receptors. American Journal of Physiology - Renal Physiology, 1999, 277, F303-F311.	1.3	67
244	Purinoceptor-Mediated Calcium Signaling in Preglomerular Smooth Muscle Cells. Hypertension, 1999, 33, 195-200.	1.3	40
245	Afferent Arteriolar Vasodilation to the Sulfonimide Analog of 11,12-Epoxyeicosatrienoic Acid Involves Protein Kinase A. Hypertension, 1999, 33, 408-413.	1.3	93
246	Early Onset Salt-Sensitive Hypertension in Bradykinin B ₂ Receptor Null Mice. Hypertension, 1999, 34, 176-180.	1.3	78
247	Cyclooxygenase-2 Modulates Afferent Arteriolar Responses to Increases in Pressure. Hypertension, 1999, 34, 843-847.	1.3	58
248	Neuronal Nitric Oxide Synthase-Dependent Afferent Arteriolar Function in Angiotensin II-Induced Hypertension. Hypertension, 1999, 33, 462-466.	1.3	28
249	Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. British Journal of Pharmacology, 1999, 127, 1399-1405.	2.7	78
250	Heterogeneous activation mechanisms in the renal microvasculature. Kidney International, 1998, 54, S17-S21.	2.6	28
251	Renal Uptake of Circulating Angiotensin II in Val5-Angiotensin II Infused Rats Is Mediated by AT1 Receptor. American Journal of Hypertension, 1998, 11, 570-578.	1.0	101
252	Interactive Nitric Oxideâ€“Angiotensin II Influences on Renal Microcirculation in Angiotensin IIâ€“Induced Hypertension. Hypertension, 1998, 31, 1255-1260.	1.3	44

#	Article	IF	Citations
253	Calcium Mobilization Contributes to Pressure-Mediated Afferent Arteriolar Vasoconstriction. Hypertension, 1998, 31, 421-428.	1.3	40
254	Neuronal nitric oxide synthase modulates rat renal microvascular function. American Journal of Physiology - Renal Physiology, 1998, 274, F516-F524.	1.3	79
255	Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. American Journal of Physiology - Renal Physiology, 1998, 275, F605-F612.	1.3	52
256	Unraveling the Mystery of Goldblatt Hypertension. Physiology, 1998, 13, 170-176.	1.6	71
257	Role of Renal Nerves in Afferent Arteriolar Reactivity in Angiotensin-Induced Hypertension. Hypertension, 1997, 29, 442-449.	1.3	52
258	Afferent and Efferent Arteriolar Vasoconstriction to Angiotensin II and Norepinephrine Involves Release of Ca ²⁺ From Intracellular Stores. Hypertension, 1997, 29, 222-227.	1.3	62
259	Renal Accumulation of Circulating Angiotensin II in Angiotensin IIâ€“Infused Rats. Hypertension, 1996, 27, 658-662.	1.3	100
260	Receptor-Mediated Intrarenal Angiotensin II Augmentation in Angiotensin IIâ€“Infused Rats. Hypertension, 1996, 28, 669-677.	1.3	165
261	Identification of a Putative Microvascular Oxygen Sensor. Circulation Research, 1996, 79, 54-61.	2.0	154